Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697734 | 0.90 | PDE4A (0.77) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL3304411 | 0.88 | PDE4A (0.63) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL3306614 | 0.88 | PDE4A (0.71) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL14889311 | 0.87 | PDE4A (0.82) | PDE4APDE4DPDE4B | |
| SCHEMBL1697759 | 0.87 | PDE4A (0.78) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL3304149 | 0.87 | PDE4A (0.65) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL3303725 | 0.86 | PDE4A (0.61) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL8165984 | 0.86 | PDE4A (0.64) | PDE4APDE4DPDE4B | |
| SCHEMBL6838082 | 0.85 | PDE4D (0.65) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL6837618 | 0.85 | PDE4D (0.65) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| WO-2008104175-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE5A, PDE3B | PDE4A 6/4885PDE4D 9/4885PDE4B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.